Printer Friendly

BAKER CUMMINS PHARMACEUTICALS CHANGES ITS NAME TO BAKER NORTON PHARMACEUTICALS

 BAKER CUMMINS PHARMACEUTICALS CHANGES ITS NAME
 TO BAKER NORTON PHARMACEUTICALS
 MIAMI, Aug. 4 /PRNewswire/ -- IVAX Corporation (AMEX: IVX) announced today that its wholly owned subsidiary "Baker Cummins Pharmaceuticals" has changed its name to "Baker Norton Pharmaceuticals, Inc." The purpose for the name change was to emphasize the relationship with Norton Healthcare Limited and its brand name marketing subsidiary, Baker Norton Limited, and to establish a common trade name to be used internationally in the marketing of pharmaceutical products. IVAX' wholly owned skin care business, Baker Cummins Dermatologicals, Inc., will continue to use the Baker Cummins trade name.
 Baker Norton Pharmaceuticals currently markets brand name products used to treat illnesses in the fields of urology, internal medicine and endocrinology. In addition, Baker Norton Pharmaceuticals is actively engaged in the research and development of both innovative new drugs and generic pharmaceuticals. It currently has one new drug application pending at the United States Food and Drug Administration and is actively pursuing the clinical development of other pharmaceutical compounds to treat a variety of indications such as Alzheimer's disease, interstitial cystitis, rheumatoid arthritis, central nervous system trauma, stroke, shock, cancer, narcotic induced constipation and AIDS.
 IVAX Corporation is a holding company with subsidiaries involved in specialty chemicals, pharmaceuticals and medical diagnostics. In addition to Baker Norton Pharmaceuticals, Inc., IVAX' principal subsidiaries include Norton Healthcare Limited, a leading manufacturer and marketer of off-patent pharmaceuticals in the United Kingdom, Ireland and other countries; Goldline Laboratories, Inc., a national marketer of off-patent prescription and over-the-counter pharmaceuticals in the United States; Baker Cummins Dermatologicals, Inc., a dermatological products company; Flori Roberts, Inc., a skin care and cosmetics company; DVM Pharmaceuticals Inc., a veterinary products company; Diamedix Corporation, a medical diagnostics company; Delta Biologicals S.r.l., a marketer of medical diagnostic tests and instruments in Italy; and IVAX Industries, Inc., a chemical specialties business.
 -0- 8/4/92
 /CONTACT: Richard C. Pfenniger Jr., senior vice president of legal affairs of IVAX Corporation, 305-590-2309/
 (IVX) CO: IVAX Corporation; Baker Cummins Pharmaceuticals; Baker Norton
 Pharmaceuticals, Inc. ST: Florida IN: MTC SU:


AW-JB -- FL001 -- 6520 08/04/92 09:28 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 4, 1992
Words:351
Previous Article:CELLULAR COMMUNICATIONS OF PUERTO RICO COMMENCES PUBLIC OFFERING OF $40 MILLION OF 8-1/4 PERCENT CONVERTIBLE SENIOR SUBORDINATED NOTES
Next Article:GAINSCO DECLARES 3-FOR-2 STOCK SPLIT AS A 50 PERCENT STOCK DIVIDEND
Topics:


Related Articles
REORGANIZATION OF BAKER CUMMINS DERMATOLOGICALS, INC.
IVAX CORPORATION ANNOUNCES THE ACQUISITION OF THREE BRAND NAME PHARMACEUTICAL PRODUCTS
IVAX CORPORATION ANNOUNCES THE APPROVAL OF ITS ABBREVIATED NEW DRUG APPLICATION FOR TOLMETIN
IVAX' SUBSIDIARY RECEIVES APPROVAL TO SELL SODIUM CROMOGLYCATE METERED DOSE INHALER IN THE UNITED KINGDOM
IVAX CONTINUES TO MANUFACTURE AND DISTRIBUTE VERAPAMIL
IVAX ANNOUNCES THE APPROVAL OF ELMIRON(R) IN CANADA
IVAX ANNOUNCES STRATEGIC ALLIANCE WITH NAPRO BIOTHERAPEUTICS REGARDING TAXOL
IVAX SUBSIDIARY GRANTED APPROVAL TO MARKET BECLOMETHASONE MET RED DOSE INHALER IN U.K.
IVAX ANNOUNCES RESULTS OF ANNUAL MEETING AND PROMOTION OF DR. JOHN K. WHISNANT
IVAX AND KNOLL ANNOUNCED SETTLEMENT OF VERAPAMIL LITIGATION

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters